Difference between revisions of "Oberneder R, et al. Eur. J. Cancer (2006) cited as Ref 560 in DOI: 10.1038/s41392-020-0110-5 (Q9823)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 42, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase I study with adecatumumab a human antibody directed against epithelial cell adhesion molecule in hormone refractory prostate cancer patients, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A phase I study with adecatumumab a human antibody directed against epithelial cell adhesion molecule in hormone refractory prostate cancer patients (English) | ||
| Property / title: A phase I study with adecatumumab a human antibody directed against epithelial cell adhesion molecule in hormone refractory prostate cancer patients (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Oberneder R, et al. Eur. J. Cancer (2006) cited as Ref 560 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Oberneder R
0 references
2006
0 references
Eur. J. Cancer
0 references
42
0 references
A phase I study with adecatumumab a human antibody directed against epithelial cell adhesion molecule in hormone refractory prostate cancer patients (English)
0 references
